For patients already meeting indications for use of a GLP-1 drug based on metabolic factors, its potential role in lowering uveitis risk could be an added consideration when selecting antihyperglycemic therapy. 1 While these possibilities are positive advancements, a commentary on the study, also published yesterday in JAMA Ophthalmology , provides some potential limitations to keep in mind when interpreting conclusions
It adds that opioid use and certain antimotility agents may compound gastric slowing, and that age over 65, female sex, and longer diabetes duration carry higher baseline gastroparesis risk
Underlying all of it is the evidence gap
Maintaining adequate Vitamin B12 levels is crucial for overall health and well-being
Improper technique introduces risk independent of the compound itself
Auerdem kann das Medikament fr Betroffene mit einem BMI ab 27 infrage kommen, wenn gewichtsbedingte Begleiterkrankungen vorliegen, wie Bluthochdruck, Diabetes Typ 2 oder Schlafapnoe